Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DERM NASDAQ:DNTH NASDAQ:FBIO NASDAQ:ZVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDERMJourney Medical$6.99-4.9%$7.19$3.54▼$8.25$171.22M0.8109,943 shs124,725 shsDNTHDianthus Therapeutics$20.59-0.4%$19.06$13.36▼$32.27$664.75M1.43352,897 shs370,878 shsFBIOFortress Biotech$1.81-2.2%$1.89$1.33▼$2.36$54.70M1.76208,765 shs118,993 shsZVRAZevra Therapeutics$11.11$10.11$6.19▼$13.16$607.49M1.871.36 million shs802,278 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDERMJourney Medical-4.90%-7.91%-0.71%-0.57%+25.95%DNTHDianthus Therapeutics-0.39%-4.23%+12.02%-5.12%-30.86%FBIOFortress Biotech-2.16%-8.12%-1.09%-1.09%-13.40%ZVRAZevra Therapeutics0.00%-1.07%+18.07%+38.88%+71.19%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDERMJourney Medical2.2193 of 5 stars3.51.00.00.02.81.70.6DNTHDianthus Therapeutics1.2237 of 5 stars3.52.00.00.00.00.80.0FBIOFortress Biotech2.4755 of 5 stars3.51.00.00.02.13.30.6ZVRAZevra Therapeutics2.0927 of 5 stars3.61.00.00.03.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDERMJourney Medical 3.00Buy$9.5035.91% UpsideDNTHDianthus Therapeutics 3.00Buy$53.00157.41% UpsideFBIOFortress Biotech 3.00Buy$21.001,060.22% UpsideZVRAZevra Therapeutics 3.11Buy$23.71113.45% UpsideCurrent Analyst Ratings BreakdownLatest DERM, FBIO, ZVRA, and DNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025ZVRAZevra TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$25.00 ➝ $29.007/2/2025DNTHDianthus TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform7/2/2025ZVRAZevra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$26.005/15/2025DERMJourney MedicalAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/14/2025ZVRAZevra TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/14/2025ZVRAZevra TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.005/13/2025DNTHDianthus TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$58.00 ➝ $50.005/13/2025DNTHDianthus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDERMJourney Medical$56.13M2.90N/AN/A$0.91 per share7.68DNTHDianthus Therapeutics$6.24M106.12N/AN/A$11.91 per share1.73FBIOFortress Biotech$57.67M0.93N/AN/A($0.06) per share-30.17ZVRAZevra Therapeutics$23.61M25.73N/AN/A$0.74 per share15.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDERMJourney Medical-$14.67M-$0.39N/AN/AN/A-14.76%-52.03%-11.28%8/11/2025 (Estimated)DNTHDianthus Therapeutics-$84.97M-$2.88N/AN/AN/A-1,544.23%-29.26%-27.87%8/6/2025 (Estimated)FBIOFortress Biotech-$46M-$2.23N/AN/AN/A-71.24%-4,712.53%-27.67%8/12/2025 (Estimated)ZVRAZevra Therapeutics-$105.51M-$1.90N/A55.55N/A-226.78%-201.05%-53.55%8/12/2025 (Estimated)Latest DERM, FBIO, ZVRA, and DNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025DNTHDianthus Therapeutics-$0.86N/AN/AN/AN/AN/A8/12/2025Q2 2025FBIOFortress Biotech-$0.31N/AN/AN/A$14.53 millionN/A8/12/2025Q2 2025ZVRAZevra Therapeutics$0.65N/AN/AN/A$22.49 millionN/A8/11/2025Q2 2025DERMJourney Medical-$0.06N/AN/AN/A$14.93 millionN/A5/14/2025Q1 2025DERMJourney Medical-$0.24-$0.18+$0.06-$0.18$12.05 million$13.14 million5/13/2025Q1 2025ZVRAZevra Therapeutics-$0.21-$0.06+$0.15-$0.06$16.96 million$20.40 million5/12/2025Q1 2025DNTHDianthus Therapeutics-$0.86-$0.82+$0.04-$0.82$0.81 million$1.16 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDERMJourney MedicalN/AN/AN/AN/AN/ADNTHDianthus TherapeuticsN/AN/AN/AN/AN/AFBIOFortress BiotechN/AN/AN/AN/AN/AZVRAZevra TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDERMJourney Medical1.071.341.03DNTHDianthus TherapeuticsN/A15.9815.99FBIOFortress Biotech1.741.721.55ZVRAZevra Therapeutics1.463.022.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDERMJourney Medical7.25%DNTHDianthus Therapeutics47.53%FBIOFortress Biotech96.51%ZVRAZevra Therapeutics35.03%Insider OwnershipCompanyInsider OwnershipDERMJourney Medical15.03%DNTHDianthus Therapeutics8.15%FBIOFortress Biotech27.90%ZVRAZevra Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDERMJourney Medical9023.30 million19.80 millionN/ADNTHDianthus Therapeutics8032.16 million29.54 millionOptionableFBIOFortress Biotech17029.57 million21.32 millionOptionableZVRAZevra Therapeutics2054.68 million53.37 millionOptionableDERM, FBIO, ZVRA, and DNTH HeadlinesRecent News About These CompaniesWhat is William Blair's Estimate for ZVRA Q3 Earnings?August 1 at 5:41 AM | marketbeat.comEquities Analysts Set Expectations for ZVRA FY2025 EarningsAugust 1 at 2:15 AM | americanbankingnews.comQ3 Earnings Forecast for ZVRA Issued By William BlairAugust 1 at 2:25 AM | americanbankingnews.comDoes Zevra Therapeutics (ZVRA) Have the Potential to Rally 117.11% as Wall Street Analysts Expect?July 31 at 10:56 AM | zacks.comWhat is William Blair's Estimate for ZVRA FY2025 Earnings?July 31 at 6:52 AM | marketbeat.comZevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type CJuly 28, 2025 | globenewswire.comReadystate Asset Management LP Purchases 616,370 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)July 23, 2025 | marketbeat.comAIGH Capital Management LLC Has $10.77 Million Stock Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)July 22, 2025 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Downgraded to Buy Rating by Wall Street ZenJuly 20, 2025 | marketbeat.comZevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)July 18, 2025 | globenewswire.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Acquired by Mystic Asset Management Inc.July 17, 2025 | marketbeat.comZevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics ...July 16, 2025 | finanznachrichten.deAre You Looking for a Top Momentum Pick? Why Zevra Therapeutics (ZVRA) is a Great ChoiceJuly 16, 2025 | zacks.com5 Small Drug Stocks to Buy Amid Trump's New Tariff ThreatsJuly 16, 2025 | zacks.comZevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and MetabolismJuly 16, 2025 | globenewswire.comZevra Therapeutics Publishes Long-Term Efficacy and Safety Results for MIPLYFFA in Niemann-Pick Disease Type CJuly 16, 2025 | quiverquant.comQZevra Therapeutics (NASDAQ:ZVRA) Reaches New 12-Month High - Time to Buy?July 16, 2025 | marketbeat.comQ2 EPS Forecast for Zevra Therapeutics Raised by AnalystJuly 16, 2025 | marketbeat.comWall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should KnowJuly 15, 2025 | finance.yahoo.comWall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should KnowJuly 15, 2025 | zacks.comHere's Why 'Trend' Investors Would Love Betting on Zevra Therapeutics (ZVRA)July 15, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDERM, FBIO, ZVRA, and DNTH Company DescriptionsJourney Medical NASDAQ:DERM$6.99 -0.36 (-4.90%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$7.00 +0.01 (+0.21%) As of 08/1/2025 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.Dianthus Therapeutics NASDAQ:DNTH$20.59 -0.08 (-0.39%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$21.00 +0.41 (+1.99%) As of 08/1/2025 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.Fortress Biotech NASDAQ:FBIO$1.81 -0.04 (-2.16%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.86 +0.05 (+2.76%) As of 08/1/2025 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.Zevra Therapeutics NASDAQ:ZVRA$11.11 0.00 (0.00%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$11.38 +0.27 (+2.43%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
